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Abstract
Background: Parkinson’s disease (PD), the second most frequent neurodegenerative disorder at old age, can be caused by
elevated expression or the A53T missense mutation of the presynaptic protein alpha-synuclein (SNCA). PD is characterized
pathologically by the preferential vulnerability of the dopaminergic nigrostriatal projection neurons.
Methodology/Principal Findings: Here, we used two mouse lines overexpressing human A53T-SNCA and studied striatal
dysfunction in the absence of neurodegeneration to understand early disease mechanisms. To characterize the progression,
we employed young adult as well as old mice. Analysis of striatal neurotransmitter content demonstrated that dopamine
(DA) levels correlated directly with the level of expression of SNCA, an observation also made in SNCA-deficient (knockout,
KO) mice. However, the elevated DA levels in the striatum of old A53T-SNCA overexpressing mice may not be transmitted
appropriately, in view of three observations. First, a transcriptional downregulation of the extraneural DA degradation
enzyme catechol-ortho-methytransferase (COMT) was found. Second, an upregulation of DA receptors was detected by
immunoblots and autoradiography. Third, extensive transcriptome studies via microarrays and quantitative real-time RT-
PCR (qPCR) of altered transcript levels of the DA-inducible genes Atf2, Cb1, Freq, Homer1 and Pde7b indicated a progressive
and genotype-dependent reduction in the postsynaptic DA response. As a functional consequence, long term depression
(LTD) was absent in corticostriatal slices from old transgenic mice.
Conclusions/Significance: Taken together, the dysfunctional neurotransmission and impaired synaptic plasticity seen in the
A53T-SNCA overexpressing mice reflect early changes within the basal ganglia prior to frank neurodegeneration. As a model
of preclinical stages of PD, such insights may help to develop neuroprotective therapeutic approaches.
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Introduction
Alpha-synuclein (SNCA) is a soluble, natively unfolded 17 kDa
protein, which acquires an antiparallel conformation after binding
to phospholipid surfaces. Its abundant expression in neurons and
the selective localization to nerve terminals point to an important
role for signaling and synaptic maintenance. Although available
evidence implicates SNCA in synaptic vesicle recycling and
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chaperone cysteine-string protein-a (CSPa) [1,2], its detailed
function is not yet understood.
SNCA missense mutations, such as A53T, as well as increased
expression of wild-type (WT) SNCA result in rare forms of
Parkinson’s disease (PD) characterized by early-onset and autosomal
dominant inheritance [3,4]. Undefined factors trigger the aggregation
of WT-SNCA within neurites and the cytoplasm of degenerating
neurons to form so-called Lewy bodies and Lewy neurites which are
microscopically visible in nearly all variants of PD, provoking the
concept that SNCA oligomerization plays a key role in the
neurodegenerative cascade [5]. While microscopic SNCA aggregates
appear particularly early in the brainstem and the olfactory bulb [6],
it is the preferential loss of dopamine (DA) secreting nerve terminals
in the striatum and the corresponding cell bodies in the substantia
nigra (SN) pars compacta [7] which underlies the deficits in
spontaneous movement activity characteristic of PD patients.
Imaging studiesofearlystage PD haveshown that the progressive
loss of dopaminergic terminals and DA signaling in the striatum is
accompanied by compensatory receptor hypersensitivity of the
postsynaptic medium spiny neurons (MSNs) evidenced by increased
DA receptor D1 and D2 (DRD1 and DRD2) levels [8].
In animal studies, striatal neurons respond to altered DA signaling
with changes in second messenger levels and transcriptional activity.
DA-regulated gene expression modulates postsynaptic excitability in
the striatum [9] and synapticplasticity asa correlate of learning [10],
until eventually loss of MSN spines occurs [11].
In PD patients, the dynamic adaptations of striatal neurons to
reduced dopaminergic innervation and to chronic pharmacolog-
ical substitution of DA are likely to influence the clinical symptoms
of the disease, the therapeutic benefit as well as the adverse long
term effects such as dyskinesias [12].
To study the initial and progressive pathogenic effects of SNCA
on intact dopaminergic terminals in vivo, we aged two independent
transgenic mouse lines (PrPmtA and PrPmtB) overexpressing
human A53T-SNCA at levels which do not result in visible protein
aggregates, nor in neuronal loss within the dopaminergic
nigrostriatal projection [13].
Our data indicate that dopaminergic neurotransmission is altered
in several ways. Striatal DA levels were modulated by SNCA
expression levels, suggesting presynaptic dysfunction in old A53T-
SNCA overexpressing mice with DA elevation. Furthermore, both
the transcriptional downregulation of the extraneural DA metab-
olizing enzyme catechol-ortho-methyltransferase (COMT) and the
upregulation of postsynaptic DA receptors (DRD1 and DRD2)
suggest that diminished amounts of DA in the extracellular space
result in compensatory efforts to maximize the postsynaptic signal.
Finally, a decreased postsynaptic transcriptional response to DA
was documented with extensive transcriptome microarray profiles
and quantitative real-time RT-PCR (qPCR) in transgenic mice at
old age, pointing to a progressive impairment of metabotropic
glutamate receptor (mGluR)-induced endocannabinoid-mediated
synaptic plasticity. This finding was supported by electrophysio-
logical studies demonstrating impaired corticostriatal long term
depression (LTD).
Taken together, our approach with aged mice elucidates at the
molecular level how A53T-SNCA overexpression in the nigrostri-
atal projection may affect synaptic strength and integrity.
Results
No evidence of neurodegeneration, but insolubility of
alpha-synuclein is detectable in the mouse mutants
studied
Similar transgene expression levels were documented in the
nigrostriatal projection of the PrPmtA and the PrPmtB mouse line
at old age, regarding the transcript levels in midbrain (Fig. 1A) and
the protein levels in striatum (Fig. 1B). The expression of
Figure 1. Human A53T-alpha-synuclein mRNA and protein expression at old age. Bar graphs depicting mRNA levels and protein levels of
transgenic human A53T-alpha-synuclein. (A) Overexpressing mouse lines PrPmtA and PrPmtB exhibit similar mRNA levels of transgenic human A53T-
alpha-synuclein in the midbrain at old age. (B) Accordingly, these mice show no differences in the protein levels of transgenic human A53T-alpha-
synuclein in the striatum, the target area of the nigrostriatal projection. Data was normalized to the loading control (Tbp transcript or beta-actin
protein) and to the mean values of PrPmtA mRNA or PrPmtA protein levels, respectively, and presented as bar graphs. N=3 animals/genotype.
‘‘pc’’ = positive control (human brain protein medley/#635301, Clontech); ‘‘nc’’ = negative control (mouse brain extract/#sc-2253, Santa Cruz
Biotechnology).
doi:10.1371/journal.pone.0011464.g001
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the striatum of PrPmtA, PrPmtB or KO animals was also similar
at young and old age (Fig. S1). Counts of tyrosine hydroxylase
(TH) positive dopaminergic neurons in consecutive sections
throughout the entire SN of PrPmtA, PrPmtB or KO animals
did not demonstrate any significant differences in nigral neuron
numbers (data not shown). Furthermore, TH immunoblots
demonstrated a similar level of dopaminergic innervation to the
striatum at both ages (Fig. S1). These data are in agreement with
our previous findings of a lack of neurodegeneration during the life
span of our A53T-SNCA overexpressing mice [13] and suggest
that these animals represent a milder form or an earlier stage of
pathology compared with other SNCA-overexpressing mouse
models which exhibit progressive striatal nerve terminal loss and
dopaminergic axon degeneration [14,15,16].
In PD, the neurodegeneration correlates to the aggregation of
alpha-synuclein, which can be detected microscopically or by
sequential fractionation of soluble versus insoluble proteins.
Although immunogold electron microscopy had been unable to
demonstrate alpha-synuclein aggregates in our A53T-SNCA
overexpressing mice, we now used an antibody (Mc42) specifically
directed against the alpha-synuclein NAC fragment which is
involved in the aggregation and analyzed the presence of insoluble
alpha-synuclein species. Insoluble monomeric bands were clearly
found, while insoluble higher molecular forms were faintly present
in the nigrostriatal tissue of some, but not all aged PrPmtA and
PrPmtB mice, similar to human PD tissue (Fig. S2). Such insoluble
alpha-synuclein bands were absent from the cortex and olfactory
bulb of aged animals and also from nigrostriatal tissue of young
animals or old WT littermates (data not shown). Although the faint
high molecular species of insoluble alpha-synuclein may be
insufficient for microscopical demonstration, these data are
compatible with a mild or early stage of pathogenesis.
Striatal DA concentration correlates with SNCA
expression levels in old mice
In view of previous data suggesting neuronal dysfunction rather
than neurodegeneration in our A53T-SNCA transgenic mice [13],
we assessed the effect of A53T-SNCA overexpression on
dopaminergic neurotransmission by measuring DA steady state
levels in striatal tissue homogenates using high pressure liquid
chromatography (HPLC). Although a deficit of DA signaling
would be expected in animals which model clinically manifest PD,
significant increases in DA concentrations were found in both
A53T-SNCA overexpressing mouse lines (PrPmtA: +32%, n=5,
p=0.011; PrPmtB: +34%, n=5, p=0.013; HPLC method 1),
compared with age-matched controls (n=6) at old age (method 1).
This observation was surprising and in contrast to a previously
documented 30% reduction of striatal DA in 3 months old mice
overexpressing an amino-acid 1–120 fragment of SNCA under
control of the TH promoter [16] and a 29% reduction of striatal
DA in 13–23 months old double mutant A30P/A53T-SNCA
overexpressing mice [15].
To validate our finding, additional mice were bred, dissected
and assayed with a similar HPLC protocol in a different laboratory
(HPLC method 2). Again, significantly enhanced DA concentra-
tions were detected at old age (PrPmtA: +15%, n=7, p=0.013)
while a trend towards increased striatal DA was seen in young
animals (Fig. 2A and 2B). Consistent significant changes of the DA
metabolites DOPAC (3,4-dihydroxyphenylacetic acid) and HVA
(homovanillic acid) were not observed (data not shown). Since the
DA alteration is cumulative and becomes significant only at old
age (Fig. 2B), we speculate that it represents an indirect effect.
Thus, A53T-SNCA overexpression appears to enhance striatal
DA levels before the advent of neurodegeneration.
Conversely, analyses of old SNCA-deficient (knockout, KO)
mice demonstrated a 27% reduction of striatal DA (n=5,
p=0.012; method 1), an observation also confirmed in the
independent laboratory (35% DA reduction, n=7, p=0.002),
while young animals exhibited less reduction of striatal DA (Fig. 2C
and 2D show the combined data). In studies of independent KO
mouse lines, a reduction of striatal DA was also observed in young
[17,18], as well as in old [19] animals. Taken together, our
findings indicate that altered striatal DA occurs in synaptic
dysfunction due to SNCA gene dosage variation, not only after
nerve terminal degeneration.
Increased striatal dopamine is accompanied by reduced
Comt expression
To understand whether the increased DA steady state level in the
striata of old A53T-SNCA overexpressing mice is accompanied by
enhanced synthesis, decreased degradation or altered compartmen-
talization of DA, the expression levels of different enzymes and
transporters responsible for DA homeostasis were determined
(Table S1). Expression changes of the dopamine transporter (Dat)
and the vesicular monoamine transporter 2 (Vmat2) which were
reported to correlate to DA distributionanomalies betweensynaptic
cytosol, vesicles and the synaptic cleft [20,21] were not detectable in
our qPCR assessment of these candidate genes. However, a highly
significant decrease of the transcript levels of the DA degradation
enzyme COMT was observed in both A53T-SNCA overexpressing
mouse lines (Fig. 3; PrPmtA: 230%, n=6, p=0.0005 and PrPmtB:
226%, n=7, p=0.0018).
In view of the extraneural localization of this enzyme, this
transcriptional downregulation probably represents a response of
the surrounding glia to abnormal DA levels in the extracellular
space.
Dopamine receptors DRD1 and DRD2 are upregulated in
the striatum of old A53T-SNCA overexpressing mice
Since Comt reduction seems a plausible effort to enhance DA
signaling, we asked whether the increased striatal DA affects
signaling in old A53T-SNCA overexpressing mice. To elucidate
the postsynaptic response to DA, expression levels of the main D1-
like and D2-like DA receptors in the striatum DRD1 and DRD2
were measured by two independent techniques. In the striatum of
old PrPmtA mice, clearly significant upregulations of DRD1 (1.63-
fold in [
3H]-SCH23390 autoradiography, Fig. 4A; 1.88-fold in
immunoblots, Fig. 4C) and of DRD2 (1.48-fold in [
3H]-spiperone
autoradiography, Fig. 4B; 1.92-fold in immunoblots, Fig. 4D) were
observed, while in the striatum of PrPmtB mice of similar age, the
upregulation was smaller and significant only in autoradiography
(1.34-fold in [
3H]-SCH23390 autoradiography, Fig. 4E; 1.13-fold
in [
3H]-spiperone autoradiography, Fig. 4F), but not in immuno-
blots with non-linear enhanced chemiluminescence detection (data
not shown). Upregulation of DA receptors and postsynaptic
hypersensitivity are known compensatory efforts associated with
deficient DA signaling [8]. The enhanced DA receptor levels
together with the downregulated Comt expression therefore may
indicate a cellular effort to compensate abnormal DA signal
transduction.
Overexpression of A53T-SNCA changes Homer1
expression in several brain regions
It remained unclear whether the reduction of Comt and the
upregulation of the DA receptors were sufficient to compensate the
SNCA and Synaptic Plasticity
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pathology in a hypothesis-free manner, extensive profiling of the
transcriptome was undertaken to screen for expression changes (i)
induced by the A53T-SNCA genotype in several brain regions and
ages or (ii) induced progressively over time, occurring consistently
and selectively only in the striatum of both transgenic lines, but not
in WT striatum or any other brain region of the three mouse lines
under study. All microarray data discussed in this publication have
been deposited in the NCBI’s database Gene Expression Omnibus
(GEO) and are accessible through GEO series accession number
GSE20547.
On a total of 54 oligonucleotide microarray chips representing
over 39,000 transcripts each, we compared 17 PrPmtA and 15
PrPmtB with 22 WT RNA extracts. Separate comparisons were
performed for striatum, midbrain/brainstem and cerebellum.
Tissues from young versus old animals were compared for each
brain region and mouse line. In view of the small fold changes
expected from complex tissues such as brain, an extensive
biomathematical workup including RMA-based normalization,
fitting with a linear model, statistical ANOVA-based evaluation,
stringent filtering, and representation of individual transcript
changes per brain region in a decision matrix were applied to
suppress background and to reveal the consistent effects. Overall,
the gene expression pattern was very similar and only few
alterations correlated to genotype or to progression with age (data
not shown).
All data were first filtered to identify transcript regulations
which correlated with the mutant genotype at both ages in all
tissues. In this analysis, we found a significant effect of A53T-
SNCA overexpression only on the transcript levels of Homer1 and
Figure 3. Reduced Comt transcript levels in striata of both
transgenic lines at old age. Bar graph illustrating the reduced
transcript levels for the extraneural dopamine degradation enzyme
catechol-ortho-methyltransferase (Comt) in the striatum of both A53T-
SNCA overexpressing mouse lines (PrPmtA and PrPmtB). Statistical
significance is reflected via asterisks (** p,0.01; *** p,0.001).
Expression changes were analyzed with the 2
2DDCt method [52].
doi:10.1371/journal.pone.0011464.g003
Figure 2. DA levels in striatal homogenates correlate to SNCA expression level. Bar graphs illustrating the dopamine levels in both A53T-
SNCA overexpressing mouse lines (PrPmtA and PrPmtB), the alpha-synuclein-deficient line (KO) and corresponding wild-type (WT) animals analyzed
in striatal tissue homogenates via HPLC. Increases of striatal dopamine (DA) levels were observed in young animals as a trend (A) and in old animals
with high significance (B) for both A53T-SNCA overexpressing mouse lines. Correspondingly, in the SNCA-deficient (KO) mice, a smaller decrease of
striatal DA levels was observed in young animals (C) which progressed in old KO animals (D). Statistical significance is reflected via asterisks (* p,0.05;
** p,0.01; *** p,0.001).
doi:10.1371/journal.pone.0011464.g002
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Hspa1b, Myef2, and D14Ertd171e (upregulated). HOMER1 pro-
teins have an established role for glutamatergic corticostriatal
neurons and in the morphogenesis of dendritic spines, assembling
group I mGluRs (mGluR1 and mGluR5) and coupling them with
inositol 1,4,5-trisphosphate (IP3) receptors and ion channels, while
excessive synaptic activity or DRD1 agonists induce the dominant
negative isoform HOMER1a as an immediate early gene (IEG)
[22]. Alterations in the expression of Homer1 in A53T-SNCA
overexpressing mice from an early age in several brain areas may
reflect altered activity and plasticity at excitatory synapses.
Striatum-specific expression changes with age represent
a progressively diminished DA response
The second biomathematical workup filtered expression
changes with progression from young to old age occurring
Figure 4. Autoradiography and immunoblot reveal elevated striatal DRD1A and DRD2 levels. Increased levels of DRD1A in lines PrPmtA
(A; 1.63-fold; p,0.0001; 3 mice/genotype; slices: WT n=39, PrPmtA n=38) and PrPmtB (E; 1.34-fold; p,0.0001; 2 mice/genotype; slices: WT n=44,
PrPmtA n=40), as well as increased levels of DRD2 in lines PrPmtA (B; 1.48-fold; p,0.0001; 3 mice/genotype; slices: WT n=35, PrPmtA n=36) and
PrPmtB (F; 1.13-fold; p,0.034; 2 mice/genotype; slices: WT n=30, PrPmtA n=25) were observed at old age. Independent data validation was
successful in immunoblot experiments employing striatal protein extracts of old PrPmtA mice for DRD1A (C; 1.88-fold; p=0.001; WT n=4, PrPmtA
n=4) and DRD2 (D; 1.92-fold; p=0.004; WT n=4, PrPmtA n=4) normalized to the beta-actin/GAPDH loading control, while the elevation did not
reach significance for PrPmtB derived samples (data not shown). Student’s t-test was employed for all statistical analyses. PSL = photo-stimulated
luminescence; pc = positive control (mouse brain extract/#sc-2253, Santa Cruz Biotechnology). Statistical significance is reflected via asterisks
(* p,0.05; ** p,0.01; *** p,0.001).
doi:10.1371/journal.pone.0011464.g004
SNCA and Synaptic Plasticity
PLoS ONE | www.plosone.org 5 July 2010 | Volume 5 | Issue 7 | e11464exclusively in the striatum of PrPmtA and PrPmtB mice, but not
in the brainstem/midbrain or cerebellum, nor in WT tissues.
R e f l e c t i n gap o s i t i v ec o n t r o l ,t h ea g i n ge f f e c tb o t hi nW Ta n d
mutant mice resulted consistently in all three brain regions in a
significant upregulation of the astrocyte hypertrophy and neural
atrophy marker glial fibrillary acidic protein (Gfap), together
with immunity- and aging-relevant lysozyme transcripts (Lzp-s
and Lyzs), and a significant downregulation of the imprinted,
maternally expressed microRNA transcript gene trap locus 2
(Gtl2) (Table S2). In contrast, the transcript levels of 57 non-
anonymous genes showed an expression change from young to
old age selectively in the striatum of lines PrPmtA and PrPmtB,
but not in the striatum of WT controls or in other brain regions
(Table S2; references are included on various genes with
established roles in DA neurotransmission, striatal synaptic
plasticity and PD). Several of these transcripts are known to
change expression in response to DA signaling, and invariably
the changes observed were consistent with a diminished striatal
DA response in PrPmtA and PrPmtB mice. Consistent
reductions were observed in transcript levels of cannabinoid
receptor 1 (Cb1 or Cnr1, 0.39-fold), ephrin B2 (Efnb2, 0.49-fold),
frequenin (Freq, 0.64-fold), Homer1 (Homer1,0 . 5 - f o l d )a n d
phosphodiesterase 7B (Pde7b, 0.37-fold). Furthermore, a reduc-
tion was observed for the cyclic adenosine monophosphate
(cAMP)-dependent transcription factor 2 (Creb2 or Atf2, 0.44-
fold), a gene known to be suppressed after axotomy of
nigrostriatal neurons and in manifest PD. CB1,E F N B 2a n d
HOMER1 have an established role in retrograde synaptic
signaling, while ATF2 and PDE7B relate to cAMP second
messenger levels downstream of DA receptors. In addition to
HOMER1, CB1 is implicated in mGluR-induced, endocanna-
binoid-mediated synaptic plasticity of excitatory synapses of the
striatum such as LTD [23]. Thus, the transcriptome data
suggest that A53T-SNCA overexpression leads to a progres-
sively diminished postsynaptic DA response and altered synaptic
plasticity in the striatum.
Independent techniques support the diminished
transcriptional response to DA in striatum
To extend this extensive transcriptome survey, we first
employed radioactive in situ hybridization and receptor autoradi-
ography to quantify the transcript and protein level of CB1 at its
site of synthesis in the striatum and its sites of destination after
anterograde axonal transport to the SN pars reticulata and the
globus pallidus (GP). CB1 expression is known to be induced in
response to chronic DA administration [24,25]. Confirming the
microarray data in the striatum of old A53T-SNCA overexpress-
ing mice, the Cb1 transcript level was significantly reduced by
15.4% (Fig. 5A, white arrow) in in situ hybridization experiments.
Furthermore, receptor autoradiography experiments showed that
CB1 binding levels in the SN and the GP were reduced by 43.3%
(Fig. 5B, white arrow) and 20.2% (Fig. 5C, white arrow),
respectively.
Second, we employed qPCR to analyze several striatal
transcript levels in old A53T-SNCA overexpressing mice in
comparison with corresponding WT and found significant
downregulations of Atf2 (PrPmtA: 219%, p=0.0299; PrPmtB:
231%, p=0.0014), Cb1 (PrPmtA: 232%, p=0.0471), Homer1
(PrPmtA: 255%, p,0.0001; PrPmtB: 219%, p=0.0348) and
Pde7b (PrPmtB: 228%, p=0.0344), genes known to be induced by
DA signaling (Table S3). These results suggest that the old A53T-
SNCA overexpressing mice exhibit a diminished DA response,
despite cellular efforts to maximize DA signaling. We assume that
the observed striatal transcriptome changes are secondary effects
of compromised DA signaling through nigrostriatal A53T-SNCA
overexpression since human SNCA immunoreactivity in the
striatum of PrPmtA and PrPmtB mice is detectable only in
synapses, but not in neurites or cell bodies [13].
Figure 5. Decreased Cb1 expression on transcript and protein level. In situ hybridization and receptor autoradiography in A53T-SNCA
overexpressing versus WT mice at old age show decreased levels of the cannabinoid receptor 1 (Cb1) mRNA in striatum (A; white arrow) and of CB1
protein in the substantia nigra (B; white arrow) as well as the globus pallidus (C; white arrow). Scale bar: 1 mm.
doi:10.1371/journal.pone.0011464.g005
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midbrain to characterize the pathological expression profile of
individual dopaminergic neurons confirmed dysregulation of Freq
(Fig. S3). This independent evidence indicates that our mouse
approach correctly identified a signaling molecule implicated in
the human disease.
Normal electrophysiological properties of striatal
neurons in WT and A53T-SNCA overexpressing mice
Since the molecular data suggest altered dopaminergic
modulation of striatal neurons and since dopaminergic synapses
modulate the signaling at glutamatergic corticostriatal projections,
we decided to perform a functional assessment of striatal
postsynaptic responses. In order to first assess a functional role
of A53T-SNCA in the regulation of intrinsic membrane
properties, single cell recordings were obtained from corticostriatal
slices prepared from WT and mice of both transgenic lines. Only
neurons electrophysiologically identified as spiny neurons were
considered for these experiments [26]. Whole-cell patch-clamp
recordings showed that intrinsic membrane properties of striatal
neurons were similar in the three groups tested and closely
resembled the electrical activity described previously for rat striatal
spiny neurons [27,28,29]. Indeed, the average resting membrane
potential was 28763 mV (n=6) in WT, 28764 mV (n=4) in
PrPmtA and 28565 mV (n=4) in PrPmtB mice. In all three
groups neurons were silent at rest. The injection of positive current
through the recording pipette induced a similar tonic firing
discharge in all groups (Fig. 6A). Membrane rectification was
present in the three groups. Striatal field potentials (FP) in WT,
PrPmtA and PrPmtB mice were evoked every 10 sec by
stimulating the cortical glutamatergic afferents to the striatum.
Increasing stimulation levels (voltage: 20–48 V; duration:
200 msec) of the corticostriatal pathway evoked FP of similar
increasing amplitude in the three groups under investigation as
shown in the plot of the input-out curves (Fig. 6B). Thus, the
intrinsic excitability of striatal neurons in old A53T-SNCA
overexpressing mice appears to be unchanged.
Lack of induction of corticostriatal long term depression
in A53T-SNCA overexpressing mice
Assessing the suggestion of altered synaptic plasticity in the
transcriptome profile on a functional level, we studied LTD in
corticostriatal slices from PrPmtA, PrPmtB and WT mice. A
typical FP was recorded by an extracellular electrode following a
single stimulation delivered from a stimulating electrode. At the
beginning of each experiment, we measured the basal FP
amplitude for 15–20 min. After the identification of a FP showing
stable baseline amplitude, three trains of stimuli (100 Hz) were
delivered. As previously described [26], this experimental protocol
induced a LTD of FP amplitude which reached a steady state
within 15 min from the tetanic stimulation (Fig. 6D, filled circle;
FP reduction at 30 min: 218.661.9%, n=15).
Conversely, while tetanic activation of cortical fibers showed
significant LTD of the FP amplitude in WT animals, in PrPmtA
and PrPmtB mice the FP did not show any long term change of
synaptic efficacy (Fig. 6D). Figure 6C shows traces obtained from
three single experiments recorded from slices prepared from
representative PrPmtA, PrPmtB and WT mice. In the traces from
the WT group the high frequency stimulation (HFS) induced a
LTD (Fig. 6C, upper traces) while in the PrPmtA and PrPmtB
groups LTD was completely absent (Fig. 6D, middle and bottom
traces). LTD normally depends on the presence of physiological
levels of DA and the D2 DA receptor activation is a permissive
factor for LTD induction [30]. In order to valuate a possible effect
of DA accumulation on corticostriatal LTD in PrPmtA and
PrPmtB mice, we performed a set of experiments in the presence
of the D2 DA receptor antagonist L-sulpiride (5 mM). However,
also in these conditions HFS did not produce any long-term
change of FP amplitude in PrPmtA and PrPmtB mice (n=4,
p.0.05, data not shown).
Thus, the electrophysiological data corroborate the conclusion
from transcriptome studies and indicate a progressive impairment
of synaptic plasticity in the striatum.
Discussion
In view of a large body of controversial in vitro data on the
physiological and pathological role of the presynaptic protein
SNCA for dopaminergic signaling, this study characterized long
term in vivo effects of SNCA mutations in the nigrostriatal
dopaminergic projection of mice. We analyzed two independent
transgenic mouse lines (PrPmtA and PrPmtB) using the neuron-
specific prion protein (PrP) promoter to overexpress human A53T-
SNCA. This missense mutation is responsible for the PARK1
variant of PD (3). An approximately 1.5-fold enhanced expression
level mimics the SNCA gene duplication which causes the PARK4
variant of PD [4] and corresponds to the overexpression level
observed in the nigrostriatal projection of these two transgenic
mouse lines. Interestingly, despite the presence of two pathogenic
SNCA mutations, these mice do not develop visible alpha-
synuclein aggregation or detectable neuron loss during their two-
year life span, but they display a progressive deficit in spontaneous
locomotion, with unchanged coordination and strength [13].
These features mirror the characteristic movement impairment in
PD which is due to deficient striatal DA signaling. In the current
study we investigated the molecular mechanisms in the striatum
which may underlie this movement deficit and neural dysfunction.
Of course, A53T-SNCA overexpression would affect neural
function also outside the nigrostriatal projection, but this model
system is particularly well characterized and these mice were
specifically generated and characterized with regard to the
transgene presence in the substantia nigra and striatum.
Our observation of increased DA content in the striatum of old
A53T-SNCA overexpressing mice was unexpected, but is similar
to findings that the triple KO of the Parkinson genes PINK1,
Parkin and DJ-1 results in an elevation of striatal DA in the
absence of neurodegeneration [31]. Increased DA levels in the
absence of neurodegeneration were also reported for PD mouse
models deficient only in Parkin (PARK2) [32] and in some in vitro
studies of A53T-SNCA [20,33,34]. In contrast, old SNCA
overexpressing mice with visible protein aggregates and a loss of
nerve terminals exhibit a reduction of striatal DA (15, 16). Our
transgenic mice do not exhibit overt neurodegeneration, visible
protein aggregation [13], a reduction in striatal TH (Fig. S1) or
any genotype-dependent increase in the Gfap transcript (as a
biomarker of astrocytosis, neurodegeneration and aging; Table
S2). The progressively increased striatal DA levels observed in
these animals (Fig. 2A and 2B) may thus be an early consequence
of A53T-SNCA overexpression prior to overt neurodegeneration.
Although it cannot be excluded that the observed increases in
striatal DA reflect a toxic gain-of-function of the A53T-SNCA
mutation, the observation of decreased striatal DA content in old
SNCA-KO mice in this study (Fig. 2C and Fig. 2D) and also by an
independent group [19] suggests a physiological modulation of DA
content by the expression level of SNCA.
In the striata of A53T-SNCA overexpressing mice, DA signals
in the extracellular space appear to be abnormal considering the
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downregulation of extraneural COMT. Both events might
constitute a compensatory effort to enhance dopaminergic
signaling in response to pathologically low DA release or high
DA reuptake. Indeed, also the DA accumulation might constitute
a similar compensatory effort to enhance DA signaling. The
notion of altered DA reuptake is conceivable in view of previous
reports of protein association between SNCA and the dopamine
transporter (DAT) [35]. On the other hand, a release problem also
seems possible in the light of recent reports that deficiency in
alpha- and gamma-synuclein leads to increased striatal DA release
and a hyperdopaminergic phenotype [36]. Current evidence
indicates that presynaptic SNCA acts together with the co-
chaperone CSPa at the soluble NSF attachment protein receptor
(SNARE) complex to regulate the exocytosis of neurotransmitter
vesicles [1].
In spite of these progressive compensatory efforts, the analysis of
striatal transcription suggests that the postsynaptic DA response is
diminishing over time. The molecular profile of the striatal age-
related changes was obtained through hypothesis-free, extensive
transcriptome studies of striatal versus brainstem/midbrain and
cerebellar tissue in young and old mice, and was validated by
independent experiments utilizing qPCR, in situ hybridization and
receptor autoradiography. Genotype analysis of all 54 microarray
chips showed primarily Homer1 changes which correlated with the
A53T-SNCA genotype in brain regions beyond the striatum by as
early as 6 months of age. HOMER1 modulates synaptogenesis
through its role as a scaffold protein for mGluRs. In contrast to the
Figure 6. Electrophysiological analysis demonstrates absent long term depression (LTD) in corticostriatal slices of old mice. Voltage
traces of striatal medium spiny neurons (MSNs) recorded in whole-cell patch-clamp during hyperpolarizing and depolarizing steps of current. Note
the similar firing pattern discharge in the representative WT, PrPmtA and PrPmtB neuron (A). Graph showing a similar input-output curve of striatal
field potential (FP) evoked by 200 msec stimuli of increasing voltage intensities applied on corticostriatal fibers in WT, PrPmtA and PrPmtB mice (B).
Representative examples of corticostriatal FP acquired 10 min before high frequency stimulation (HFS) protocol and 40 min after HFS in WT, PrPmtA
and PrPmtB mice (C). Time-course of FP amplitudes showing the induction of LTD only in WT mice, whereas no long-lasting change of the FP
amplitude in PrPmtA and PrPmtB mice is monitored up to 40 min following the HFS protocol application (D). The significance level was established at
p,0.001 (**) and p,0.0001 (***).
doi:10.1371/journal.pone.0011464.g006
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short splice variant HOMER1a is induced by neurotransmission
activity as an IEG, acts as endogenous negative modulator of the
mGluR/IP3 receptor signaling complex and prevents excessive
glutamate-induced neuronal activity [37]. The observation of
genotype-dependent alterations of Homer1 transcript levels thus
suggests that A53T-SNCA overexpression affects glutamate
neurotransmission throughout the brain and that Homer1 expres-
sion is a useful marker of this effect. Within the striatum, the most
striking changes were observed in several transcripts known to be
regulated by dopaminergic innervation. DA signaling induces
expression of the mGluR modulator HOMER1a [38,39], CB1
[24,25] and PDE7B [40]. Conversely, reduced expression levels of
striatal Homer1 and mGluR1a were previously observed after
dopaminergic neuron death in the neurotoxic 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD [41],
while animals with nigrostriatal denervation exhibit DA supersen-
sitivity and abnormal expression of several IEGs, such as
HOMER1a [9]. Axotomy of nigrostriatal dopaminergic neurons
is reported to suppress the expression of Atf2 [42,43]. Therefore,
the reduced transcript levels of all these genes in the striatum of old
A53T-SNCA overexpressing mice indicate a progressively dimin-
ished postsynaptic DA response.
Our electrophysiological investigation was carried out since DA,
CB1 and mGluRs are known prerequisites of LTD, the most
prominent form of synaptic plasticity in the striatum, particularly
for the indirect pathway MSNs. Striatal LTD requires the
activation of DA receptors and mGluRs with the consequent
release of endocannabinoids and a long-lasting inhibition of
neurotransmitter release [23,30,44]. Neurotoxic DA depletion in
animal models of end-stage PD is associated with a decrease in
striatal synaptic plasticity, which progresses to a loss of spines and
glutamatergic synapses on indirect pathway neurons [11]. The
present analysis of genetic mouse models of PD demonstrates that
loss of LTD is associated with the A53T-SNCA mutation or
SNCA protein overexpression.
How can pathogenesis be induced, while visible Lewy-
pathology is undetectable and insoluble alpha-synuclein is
mainly monomeric in our mice? We speculate that increasing
degrees of alpha-synuclein overexpression would first saturate
all interaction sites within its physiological localizations such as
the synapse and also the somatodendritic compartment, before
solubility becomes impaired and then reversible as well as
irreversible aggregation processes take place. In the synapse, an
alpha-synuclein gain-of-physiological-function would interfere
with the cycling of neurotransmitter vesicles [45] and could lead
to an accumulation of dopamine, as was recently observed also
in C. elegans [46].
In conclusion, our findings (summarized in Fig. 7) demonstrate
that A53T-SNCA overexpression in the murine nigrostriatal
system is associated with a syndrome of progressive synaptic
dysfunction, in the absence of neurodegeneration. This striatal
dysfunction is evident by an enhancement of DA levels, a reduced
expression of the extraneural DA degradation enzyme COMT
and an upregulation of postsynaptic DA receptors, three
abnormalities which may constitute compensatory efforts to
maximize signal strength. Further, we identified Homer1 as
molecular biomarker of this dysfunction and demonstrated a
progressive impairment of synaptic plasticity at the molecular and
electrophysiological level. Taken together, we suggest that these
Figure 7. Synopsis of progressively abnormal synaptic signaling in old A53T-SNCA striata. This schematic illustration summarizes the
progressive pathology of a striatal MSN dendritic spine. The MSN is innervated by nigrostriatal dopaminergic input where the presence of pathogenic
overexpressed A53T-SNCA causes elevated presynaptic DA. In glia cells, the DA degradation enzyme COMT is transcriptionally downregulated,
suggesting altered extracellular turnover of DA. Postsynaptically, the upregulation of DRD1A and DRD2 and the decreased transcript levels of several
DA-inducible genes suggest a progressively diminishing striatal DA response. In parallel, the plasticity of corticostriatal glutamatergic synapses is
affected through retrograde signaling, leading to the absence of LTD.
doi:10.1371/journal.pone.0011464.g007
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prior to the advent of neurodegeneration, and may thus be useful
to understand molecular mechanisms occurring in early stages of
the disease and to evaluate preventive therapies.
Materials and Methods
Animal welfare
Mice were housed at the FELASA-certified Central Animal
Facility (ZFE) of Frankfurt Goethe University Medical School
according to the animal husbandry guidelines of the German
Animal Welfare Act, the Council Directive of November 24
th,
1986 (86/609/EWG) with Annex II and the ETS123 (European
Convention for the Protection of Vertebrate Animals).
All the experiments were conducted in conformity with the
European Communities Council Directive of November 1986
(86/609/ECC).
Animal breeding and dissection
Mice overexpressing A53T-SNCA and mice lacking endoge-
nous SNCA were prepared as previously described [13,47].
Animals were housed in the same room under 12/12 h light/dark
cycle with food and water ad libitum. The two mouse lines
overexpressing A53T-SNCA, PrPmtA and PrPmtB, were com-
pared with their background strain FVB/N as WT controls while
the SNCA-deficient (KO) mouse line was compared with its
background strain 129sv/ev as WT control. Two age groups were
analyzed for each genotype; 6-month-old animals represented
adult animals prior to the development of motor impairment
(young age), while at least 18-month-old animals exhibiting mild
motor impairments represented the early stage of clinically
manifest disease (old age). Following cervical dislocation, brain-
stem/midbrain, striatum and cerebellum were dissected, frozen in
liquid nitrogen and stored at 280uC for molecular and
biochemical analyses or fixed in 4% paraformaldehyde for
immunohistochemistry. For in situ hybridization and autoradiog-
raphy, brains were frozen in 2-methylbutane cooled in dry ice and
then sliced in 20 mm-thick coronal sections, according to the
Lehmann mouse brain atlas [48]. Sections were thaw-mounted
onto RNase-free gelatin/chrome alum coated slides and dried
briefly at 30uC and stored at 280uC until use. Adjacent sections
were stained with cresyl-violet to verify the anatomical position.
Immunoblots
Following tissue homogenization with radioimmunoprecipita-
tion assay (RIPA) buffer (50 mM TRIS pH 8.0, 150 mM NaCl,
1% Triton X-100, 0.5% Na-deoxycholate, 0.1% SDS) supple-
mented with complete protease inhibitor cocktail (Roche,
Mannheim, Germany), samples were incubated at 4uC, rotating
for 20 min. Homogenates were centrifuged for 15 min at 4,500 g
and 4uC and supernatants were collected. 20 mg of protein were
separated in 10–12% tris-glycine polyacrylamide, depending on
the size of the protein to be detected, and transferred onto a
polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Munich,
Germany). Membranes were blocked with 5% fat-free milk in
phosphate buffered saline/Tween (PBS/T; 0.1%), for 1 hour (h) at
room temperature (RT) and incubated with the primary antibody
[anti-SNCA, 1:500 dilution (#610787, BD Transduction Labo-
ratories, San Jose, CA, USA); anti-SNCA [4B12], 1:200 dilution
(#1904, abcam); anti-TH, 1:1,000 dilution (#P40101, Pel-Freez,
Rogers, AR, USA); anti-b-actin, 1:15,000 dilution (#A5441,
Sigma Aldrich, Hamburg, Germany)] in PBS/T overnight at 4uC,
washed 3 times with PBS/T and incubated with the secondary
antibody (alkaline phosphatase conjugated anti-mouse antibody,
1:15,000 dilution (#NA931V, GE Healthcare, Munich, Germany)
for 1 h at RT. After washing, the secondary antibody was detected
with a chemiluminescent substrate (Pierce SuperSignal West Pico
Chemiluminescent; Thermo Fisher Scientific Inc., Rockford, IL,
USA). Densitometric analyses utilized TotalLab software (Amer-
sham Biosciences, Freiburg, Germany).
Sequential Extraction of a-Synuclein
Subcellular fractionation of human cerebral cortex samples and
subdivided mice brain was performed as described previously [49].
Briefly, human tissue was homogenized in 10 vol and mouse tissue
in 5 vol of TBS+ (Tris-buffered saline plus Complete protease
inhibitor; Roche Diagnostics, Mannheim, Germany) and spun for
30 min at 120.0006g. The resulting supernatant represented the
TBS+ soluble fraction. The pellet was then extracted sequentially
with 1 ml of TBS+ containing 1% of Triton X-100, and TBS+,
1 M sucrose, following extraction with RIPA buffer (50 mM Tris-
HCl, pH 7.4, 175 mM NaCl, 5 mM EDTA, 1% NP-40 and 0.5%
sodium deoxycholate) and 0.1% SDS. The detergent-insoluble
pellet was solubilized in 8 M urea/5% SDS. The supernatants
were supplemented with glycerol and stored at 280uC. Protein
extracts (37 mg each) were fractionated on 17% SDS-PAGE and
blotted on a nitrocellulose membrane (Whatman, Dassel, Ger-
many). Immunoblots were blocked in 5% dry milk in TBST buffer
(10 mM Tris pH 7.5; 0.15 M NaCl; 0.1% Tween 20) and
subsequently probed with 15G7-a-syn antibody (1:20) (AG
Scientific, San Diego, CA) and Mc42 (1:3000) (Transduction
laboratories, Lexington, KY). Anti-b-actin (1:10.000) (A4700;
Sigma) was used as loading control. Bound antibodies were
visualized with horseradish peroxidase-conjugated secondary
antibodies and enhanced chemiluminescence (ECL or ECL
plus,
GE Healthcare) and exposure to hyperfilm (GE Healthcare). Brain
tissues subjected to sequential protein extraction were analyzed 3
times on different Western blots with similar results.
HPLC assay of striatal DA and its metabolites
Method 1 (used in Wu ¨rzburg): Striatal samples were thawed,
weighed and sonicated in 0.05 M perchloric acid for 60 seconds
[24] resulting in 10% (w/v) homogenate suspensions. These were
centrifuged at 48,000 g for 20 min at 4uC, and 50 ml samples of
the supernatants injected directly into a HPLC system with
electrochemical detection (ED) (Gynkotek GmbH, Germering,
Germany) for analysis of tissue DA according to the method as
previously reported [50]. The HPLC system consisted of an
AGILENT 1100 series (Bio-Rad, Munich, Germany), a Nucleosil
120-5C18 reverse phase (25064.6 mm) analytical column (Ma-
cherey-Nagel, Du ¨ren, Germany), an electrochemical detector
(model 1640; Bio-Rad, Munich, Germany), and a mobile phase
(flow rate: 1.5 ml/min) containing 0.1 M sodium phosphate
buffer, pH 3.9, 84% (v/v) and 16% (v/v) methanol containing
0.1 mM ethylenediaminetetraacetic acid (EDTA), 0.65 mM 1-
octanesulfonic acid and 0.5 mM triethylamine. The detector
potential was set at +0.75 V relative to the Ag/AgCl reference
electrode. The signal from the detector was recorded and data
analyses were performed using an AGILENT Chem Station for
LC9D (Bio-Rad, Munich, Germany). Concentrations were
calculated from the peak height with the aid of an external
standard. The investigator was blind to the animal’s genotype.
Method 2 (used in Madrid): Striata were homogenized in 20–40
volumes of cold 150 mM potassium phosphate buffer, pH 6.8.
Each homogenate was aliquoted to allow parallel measurements of
protein concentrations according to the method of Lowry as well
as DA and homovanillic acid (HVA) content using HPLC-ED,
following a previously published method [51]: One aliquot was
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sodium disulfite, 0.9 mM EDTA and the corresponding internal
standard (dihydroxybenzylamine for catecholamines). Samples
were centrifuged for 3 min at 15,000 g and supernatants were
injected directly into the HPLC system which consisted of the
following components: The pump was an isocratic Spectra-Physics
8810. The column was a RP-18 (Spherisorb ODS-2; 150 mm,
4.6 mm, 5 mm particle size; Waters, Massachusetts, USA). The
mobile phase, previously filtered and degassed, consisted of
100 mM citric acid, 100 mM sodium acetate, 1.2 mM heptane
sulphonate, 1 mM EDTA and 7% methanol (pH 3.9). The flow
rate was 0.8 ml/min. The effluent was monitored with a
coulochemical detector (Coulochem II, ESA) using a procedure
of oxidation/reduction (conditioning cell: +360 mV; analytical cell
#1: +50 mV; analytical cell #2: 2340 mV) that reaches a
sensitivity of 50 nA (10 pg per sample). The signal was recorded
on a Spectra-Physics 4290 integrator. The results were obtained
from the peaks and calculated by comparison with the area under
the corresponding internal standard peak. Values were expressed
as ng per mg of protein.
DRD1-/DRD2-Immunoblots
In contrast to other immunoblot experiments, the protein
samples used for the detection of dopamine receptors DRD1 and
DRD2 were not boiled at 95uC for 5 min before being loaded
onto the gel after personal communication with the group that
generated the DRD1A antibody. Instead, the protein samples
were heated at 40uC for 5 min. The following mouse monoclonal
antibodies were used: anti-DRD1A, 1:200 dilution (#sc-33660,
D1DR (SG2-D1a); Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-DRD2 1:200 dilution (#sc-5303, D2DR (B-10); Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), 1:10,000 dilution
(#CB1001, mAb (6C5); Calbiochem/Merck, Darmstadt, Ger-
many) and anti-b-actin, 1:10,000 dilution (#A5441, Clone AC-15;
Sigma Aldrich, Hamburg, Germany).
DRD1-/DRD2-Autoradiography
Preparation of brain slices. After cervical dislocation of the
mice, the brains were carefully dissected, immediately frozen in
dry ice cooled 2-methylbutane and stored at 280uC until use.
Before the preparation of the 14 mm-thick horizontal brain slices,
the brains were equilibrated in the cryostat chamber to a
temperature of 21561uC. Sections were melted onto super
frosted glass slides (Menzel GmbH, Braunschweig, Germany), air
dried and finally stored at 280uC until use.
Autoradiography of DRD1 and DRD2 binding. During
DRD1 autoradiography, horizontal brain slices were incubated for
1 h at RT in a buffer containing 1 M Tris, 120 mM NaCl, 5 mM
KCl, 2 mM CaCl2, 1 mM MgCl2 and 2 nM tritium [
3H]-labeled
SCH23390 (85 Ci/mmol). In case of DRD2 autoradiography,
horizontal brain sections were incubated for 1 h on ice in a buffer
containing 50 mM Tris citrate (pH 7.4), 120 mM NaCl and
0.5 nM [
3H]-spiperone (15 Ci/mmol). To determine the non-
specific binding of [
3H]-SCH23390 as well as [
3H]-spiperone,
slices were incubated in the same way as previously described,
both radioligands being replaced by high dosed DA (50 mM) and
haloperidol (10 mM), respectively. The corresponding signal values
were subtracted as non-specific background from the DRD1- and
DRD2-specific signal values measured. Following incubation,
slices were washed twice for 5 min in ice-cooled buffer, dipped in
ice-cooled distilled water and finally dried under a stream of cold
air. Autoradiographies were generated by exposing the slices to a
[
3H]-sensitive Fujifilm imaging plate for 4–7 days and scanning
the signals via a Fujifilm FLA-7000 scanner. Measurement and
analysis of the autoradiographies were performed by using
Multigauge FujiFilm software.
Data Analysis. Digital photo-stimulated luminescence values
per area (PSL/mm
2) for both hemispheres of each horizontal
brain slice were evaluated. Only those hemispheres were included
for analysis, which differed less than 20%. Mean values of the two
hemispheres of each slice were calculated and the corresponding
background values were subtracted, respectively. The data of each
individual experiment was checked for biological outliers.
Finally, the data of three independent DRD1 autoradiography
experiments as well as the data of two independent DRD2
autoradiography experiments was normalized to the WT signals
on the corresponding films and taken together. Student’s t-test was
used to determine significance.
Transcriptome analyses with oligonucleotide microarray
chips
Tissue was dissected from the brain of young mice (2 WT/2
PrPmtA/2 PrPmtB striata, 2 WT/2 PrPmtA/2 PrPmtB brain-
stems/midbrains, 2 WT/2 PrPmtA/2 PrPmtB cerebella) and old
mice (4 WT/2 PrPmtA/2 PrPmtB striata, 6 WT/4 PrPmtA/3
PrPmtB brainstems/midbrains, 6 WT/5 PrPmtA/4 PrPmtB
cerebella). Tissues from individual, particularly old mice up to
28 months age were included here to strengthen the definition of
progression markers reflecting old age. Double-stranded cDNA
was synthesized from total RNA extracts from the brain tissues
using a Superscript Choice Kit (Invitrogen) with a T7-d(T)24
primer incorporating a T7 RNA polymerase promoter (Metabion,
Martinsried, Germany). Subsequently, cRNA was prepared and
biotin labeled by in vitro transcription (Enzo Life Sciences, Lo ¨rrach,
Germany). Labeled cRNA was fragmented by incubation for
35 min at 94uC min in the presence of 40 mM Tris-OAc (pH 8.1),
100 mM KOAc, and 30 mM MgOAc. Labeled, fragmented
cRNA (15 mg) was hybridized for 16 h at 45uC to a 430 2.0 mouse
genome array (Affymetrix, Santa Clara, CA, USA). After
hybridization, gene chips were automatically washed and stained
with streptavidin–phycoerythrin using a fluidics station. The probe
arrays were scanned at 0.7 mm resolution using a Genechip
System Scanner 3000. Scanned images were subjected to visual
inspection and analyzed using the Affymetrix’s GCOS version 1.3.
The biomathematical analyses were performed by the IMGM
Institute (Martinsried, Germany). To define the influence of the
factors genotype or age on the transcriptome, linear models were
applied. To determine the effect of genotype, the overlap between
PrPmtA versus WT, and PrPmtB versus WT, changes were
examined. For the mathematical-statistical assessment of data,
their visualization and functional correlation, the software
platform R (version 2.4.0) and the pertinent bioconductor
packages Limma and Affy as well as the Spotfire Decision Site
for Functional Genomics 9.0 and diverse tools at the panther
website (http://www.pantherdb.org) were used. Initially, the
expression data from all chips were normalized with the RMA
(Robust Multichip Average) method to yield log2-transformed
signal values. Global gene expression was compared between chips
using scatter plots and Pearson’s R correlation coefficients. The
signal values were then averaged for the individual subgroups and
transformed to linear scales to derive fold change values.
Differences between subgroups were extracted as contrasts and
analyzed with the moderated F-test (empirical Bayes method)
including a correction step for multiple testing with the 5%-FDR-
based method of Benjamini and Hochberg. To attribute significant
regulations to individual genes, a decision matrix was generated
based on the function decide tests within the Limma option
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by values of +1o r21, respectively. All microarray data discussed
in this publication are MIAME compliant; raw data have been
deposited in the MIAME compliant NCBI’s database Gene
Expression Omnibus (GEO) [49] and are accessible through GEO
series accession number GSE20547.
In situ hybridization of Cb1 mRNA
Analyses of Cb1 transcript levels were performed as previously
described [52]. Briefly, sections were fixed in 4% paraformalde-
hyde for 5 min, rinsed twice in PBS, acetylated by incubation in
0.25% acetic anhydride and prepared in 0.1 M triethanolamine/
0.15 M sodium chloride (pH 8.0) for 10 min. They were rinsed
again in 0.3 M sodium chloride/0.03 M sodium citrate, pH 7.0,
dehydrated and delipidated via an ethanol/chloroform series. A
mixture (1:1:1) of the three 48-mer oligonucleotide probes
complementary to bases 4–51, 349–396 and 952–999 of the rat
Cb1 cDNA (Du Pont NEN; the specificity of the probes used was
assessed by Northern blot analysis) was 39-end labeled with [
35S]-
dATP using terminal deoxynucleotidyl transferase. The sections
were hybridized with [
35S]-labeled oligonucleotide probes
(7.5610
5 dpm per section), washed, exposed to X-ray film (Kodak)
for one week and developed (D-19, Kodak) for 6 min at 20uC. The
intensity of the hybridization signal was assessed by measuring the
grey levels in the autoradiographic films using computer-assisted
videodensitometry. Adjacent brain sections were co-hybridized
with a 100-fold excess of cold probe or with RNase to determine
the specificity of the signal (data not shown). Details of this
procedure have been published previously [53].
Autoradiography of CB1 binding
The protocol used was previously described. Briefly, slide
mounted brain sections were incubated for 2.5 h at 37uCi na
buffer containing 50 mM TRIS with 5% bovine serum albumin
(BSA, fatty acid-free), pH 7.4, and 10 nM [
3H]-CP-55,940 (Du
Pont NEN) prepared in the same buffer, in the absence or the
presence of 10 mM non-labeled CP-55,940 (Sigma Aldrich,
Hamburg, Germany) to determine the total and the non-specific
binding, respectively. Following incubation, slides were washed in
50 mM TRIS buffer with 1% BSA (fatty acid-free), pH 7.4, for
4h( 2 62h )a t0 uC, dipped in ice-cold distilled water and dried
under a stream of cool dry air. Autoradiograms were generated by
apposing the labeled tissues, together with autoradiographic
standards ([
3H] micro-scales; Amersham Biosciences, Freiburg,
Germany), to [
3H]-sensitive film ([
3H]-Hyperfilm; Amersham
Biosciences, Freiburg, Germany) for a period of 2 weeks.
Autoradiograms were developed (D-19, Kodak) for 4 min at
20uC, and the films were analyzed and quantified in a computer-
assisted videodensitometer using standard curves generated from
[
3H]-standards.
Transcript level assays with quantitative real-time RT-PCR
Total RNA was extracted from mouse brain tissues with
TRIZOL (Invitrogen, Karlsruhe, Germany) and digested with
DNase (amplification grade I; Invitrogen, Karlsruhe, Germany)
following the manufacturers’ instructions. In the case of the striata,
RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) was
used for RNA extraction. 2 mg of DNase treated RNA were
reverse transcribed in a 36 ml reaction, using pd(N)6 and NotI-
d(T)18 primers (First Strand cDNA Synthesis Kit; Amersham
Biosciences, Freiburg, Germany). All qPCR reactions were carried
out in 20 ml containing 0.5 ml of cDNA template, 10 mlo f2 6
TaqManH Universal Master Mix (Applied Biosystems, Foster City,
CA, USA) and 1 ml TaqManH gene expression assay on an ABI
Prism 5700 sequence detection system. The following PCR
protocol was used: ‘‘stage 1’’ 2 min at 50uC; ‘‘stage 2’’ 10 min
at 95uC; ‘‘stage 3’’ 15 sec at 95uC/40 sec at 60uC( 4 0r e p e a t s ) .T h e
following mouse TaqManH assays were employed: SNCA
Hs01103383_m1, Atf2 Mm00833804_g1, Cb1 Mm00432621_s1,
Comt Mm00514377_m1, Dat (=Slc6a3) Mm00438388_m1, Ddc
Mm00516688_m1, Gch1 Mm00514993_m1, Homer1 Mm00516275_
m1, Maoa Mm00558004_m1, Maob Mm00555412_m1, Pde7b
Mm00450009_m1, Spr Mm00488430_m1, Th Mm00447546_m1,
Vmat2 (=Slc18a2) Mm00553058_m1 and Tbp Mm00446973_m1 as
internal standard for normalization. Expression changes were
analyzed with the 2
2DDCt method [52].
Analysis of frequenin mRNA levels in individual neuromelanin-
positive SN DA neurons from human post mortem Parkinson’s
disease and matched control brains via UV-lasermicrodissection
(UV-LMD) and qPCR was carried out essentially as described
[54] using the human TaqManH assay Freq Hs00977274 (60 bp,
spanning exon boundary 4-5; Applied Biosystems). Standard curve
for qPCR quantification was generated using serial dilutions of
cDNA (3, 0.3 and 0.03 ng) derived from human SN tissue RNA
(Ambion) as template in duplicates in n=3 independent qPCR
runs. Fluorescence threshold for all data for Ct analysis was 0.3;
human freq cDNA standard-curve parameters: slope: 3.2460.01;
R2: 1.0060.01, Y-Intercept: 30.8260.34.
Preparation and maintenance of slices for
electrophysiological recordings
Corticostriatal coronal slices (thickness, 270 nm) were cut from
18-month-old male WT, PrPmtA and PrPmtB mice (n=10 mice
per genotype) using a vibratome. Preparation and maintenance of
rat corticostriatal slices have been previously described [26,55,56].
A single slice was transferred to a recording chamber and
submerged in a continuously flowing Kreb’s solution (34uC; 2.5–
3 ml/min) bubbled with a 95% O2–5% CO2 gas mixture. The
composition of the solution was: 126 mM NaCl, 2.5 mM KCl,
1.2 mM MgCl2, 1.2 mM NaH2PO4, 2.4 mM CaCl2,1 0 m M
glucose, and 25 mM NaHCO3.
Electrophysiology
Striatal MSNs were visualized using differential interference
contrast (Nomarski) and infrared microscopy (Olympus Europa
GmbH, Hamburg, Germany). Patch-clamp recordings were
performed with borosilicate glass pipettes (4–7 MV) filled with
intracellular solution: 145 mM K
+-gluconate, 0.1 mM CaCl2,
2 mM MgCl2, 0.1 mM ethyleneglycoltetraacetic acid (EGTA),
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 0.3 mM guanosine triphosphate (GTP) and 2 mM
Mg-ATP, adjusted to pH 7.3 with KOH. Signals were amplified
with a Multiclamp 700B amplifier, recorded in current-clamp
mode and stored on PC using pClamp10 (Axon Instruments,
Foster City, CA, USA). Whole-cell access resistance was 5–30 MV.
For extracellular recordings an Axoclamp 2B amplifier (Axon
Instruments, Foster City, CA, USA) was used and recording
electrodes, filled with 2 mol/l NaCl (15–20 MV), were invariably
placed within the striatum. The FP amplitude was defined as the
average of the amplitude from the peak of the early positivity to
the peak negativity and the amplitude from the peak negativity to
peak late positivity [57]. A corticostriatal FP was evoked every
10 sec by means of a bipolar electrode connected to a stimulator
unit (Grass Telefactor, USA). The stimulating electrode was
located in the white matter between the cortex and the striatum to
activate corticostriatal fibers. For the input-output curve, a
stimulus of increasing voltage intensity and constant duration
(200 msec) was delivered every 10 sec prior the onset of each
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FP amplitudes in respect to the relative control amplitude values,
the latter representing the mean of responses recorded during a
stable period. For induction of LTD, a conditioning high
frequency stimulation (HFS) protocol of three trains (3 sec
duration at 20 sec intervals) was delivered at 100 Hz frequency.
Only one experiment involving a conditioning HFS protocol was
conducted on a single slice. Offline analysis and statistic was
performed using Clampfit 10 (Axon Instruments, Foster City, CA,
USA) and GraphPad Prism 3.02 (GraphPad Software, San Diego
CA, USA) software. Analysis of variance (ANOVA) and
Bonferroni’s post hoc test were used for statistical analysis. Values
given in the figures and text are mean 6 standard error of the
mean (SEM).
Statistical analysis
Statistical analysis of DA concentration, in situ hybridization,
receptor autoradiography and qPCR was performed using
unpaired t-tests via the Prism 3 software (GraphPad, La Jolla,
CA, USA). Data are presented as mean 6 SEM. Significant
differences were highlighted with asterisks (* p,0.05; ** p,0.01;
*** p,0.001).
Supporting Information
Figure S1 SNCA/A53T-SNCA and TH immunoblots of striatal
protein extracts at young and old age. Illustration of tyrosine
hydroxylase (TH; left panel) and a-synuclein (murine SNCA and
human A53T-SNCA; right panel) protein levels in all mutant
mouse lines (PrPmtA, PrPmtB and KO) as well as wild-type (WT)
animals (FVB/N and 129sv/ev) at both ages investigated. Both
TH and SNCA/A53T-SNCA immunoblots demonstrate that
dopaminergic innervation to the striatum is preserved at both ages
studied and that SNCA does not vary with age in these animals. As
expected, no endogenous SNCA was present in striatal tissues of
the KO mice (data not shown). Equal loading was controlled with
b-actin. N=4 animals per age and genotype.
Found at: doi:10.1371/journal.pone.0011464.s001 (5.91 MB TIF)
Figure S2 Insoluble alpha-synuclein in human PD and old
A53T-SNCA brain. Tissue samples were subjected to sequential
protein extraction as described in materials and methods,
including cortex tissue (A) from a patient with Parkinson’s disease
(PD; BrainNet, Munich) as positive control and (B) from healthy
human individual as negative control, together with samples of
striatum and midbrain from (B) 18-month-old PrPmtA mice and
(C) PrPmtB mice. The immunoblots were detected with an
antibody recognizing the NAC fragment of human and mouse
alpha-synuclein. Thus, signals in TBS-soluble fractions correspond
to soluble alpha-synuclein, T/T signals correspond to membrane-
bound alpha-synuclein and bands in the urea (U) fractions
represents insoluble alpha-synuclein. (A) In the analyzed disease
patient, alpha-synuclein was detected in the soluble (TBS),
membrane-bound (T/T) and in the insoluble (U) extracts. (B)
Comparable to signals seen in the PD patient, also the the
insoluble fraction of PrPmtA nigrostriatal tissue contained
monomeric alpha-synuclein and faint high molecular bands. In a
healthy human control individual, alpha-synuclein signal was
detected only in soluble and membrane-bound fraction, but not in
the insoluble fraction of brain tissue. (C) A prominent insoluble
monomeric (a-Syn)1 signal was detectable in midbrain of a 18-
month-old PrPmtB transgenic mice (left panel), and (right panel)
insoluble alpha-synuclein was found as high molecular forms (a -
Syn)n in striatum and as monomeric species in striatum and
midbrain of a second 18-month-old PrPmtB mouse, but not in a
third analyzed mouse. Bands of insoluble anti-alpha-synuclein-
immunoreactivity were highlighted with asterisks. Beta-actin was
used as loading control.
Found at: doi:10.1371/journal.pone.0011464.s002 (4.54 MB TIF)
Figure S3 Altered frequenin mRNA expression of individual
substantia nigra dopaminergic neuron from human PD post
mortem midbrain via UV-LMD and qPCR. Neuromelanin-
positive [NM(+)] neurons were isolated via UV-laser microdissec-
tion from cresylviolet-stained horizontal midbrain cryo-sections
from PD and control brains (n=5 each, provided from the
German BrainNet). Left: Scatter plot of frequenin mRNA levels in
PD and control brains. mRNA expression of each pool of 15 NM-
and tyrosine hydroxylase- (TH-) positive SN DA neurons is given
as pg-equivalents of total cDNA, derived from human SN tissue,
per cell (determined via qPCR, standard curve quantification).
Bars represent mean6SEM frequenin mRNA levels for all
analyzed SN DA pools of each individual brain, (age, gender
and RNA integrity number (RIN) for each brain is given at the
bottom). Right: Mean mRNA level of frequenin was significantly
higher in individual NM(+) SN DA neurons from PD brains
compared to those of controls (PD: 17.8961.54 pg, n=33;
controls 6.7861.07, n=27; p=2610‘27).
Found at: doi:10.1371/journal.pone.0011464.s003 (5.21 MB TIF)
Table S1 Expression analysis of candidate genes involved in
dopamine homeostasis via qPCR. Transcript expression levels of
enzymes involved in dopamine synthesis or degradation as well as
transporters responsible for reuptake and sequestration of dopamine
in presynaptic storage vesicles in the striatum of old A53T-SNCA
overexpressing mice (PrPmtA: n=3–6; PrPmtB: n=3–8) and
corresponding wild-type animals (WT: n=3–6) were studied via
qPCR. The only transcript, which was consistently altered in both
transgenic mouse lines PrPmtA and PrPmtB at old age, was the
transcript for the extraneuronal dopamine-degrading enzyme
catechol-ortho-methyltransferase (Comt). Significant transcript ex-
pression changes are presented in percentage 6 SEM and
highlighted with black arrows and asterisks(** p,0.01; *** p,0.001).
Found at: doi:10.1371/journal.pone.0011464.s004 (0.03 MB
XLS)
Table S2 Transcriptome excerpt of striatum, brainstem/mid-
brain and cerebellum of young and old A53T-SNCA overex-
pressing mice. Significantly down- (-1) or up- (+1) regulated
transcripts are clustered for DA-induced genes, alpha-synuclein
interacting proteins, signaling proteins, transcription/translation
and adhesion proteins. References with relevance for PD
pathogenesis are given for each transcript.
Found at: doi:10.1371/journal.pone.0011464.s005 (0.04 MB
XLS)
Table S3 Independent validation of transcriptional dysregula-
tion of dopamine-induced genes by qPCR. Striatal mRNA
expression levels in old PrPmtA and PrPmtB mouse brains were
documented. Significant changes are highlighted with arrows, the
significance values is illustrated by asterisks (* p,0.05; ** p,0.01;
*** p,0.001). N=4 per genotype.
Found at: doi:10.1371/journal.pone.0011464.s006 (0.03 MB
XLS)
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